La cadena de opciones muestra datos clave de las opciones de acciones de BioCardia a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioCardia..

BioCardia (NASDAQ:BCDA) Bolsa, Cadena de Opciones

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-1024x576.png" alt="" class="wp-image-8014" style="width:928px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-768x432.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The car trader that recently shifted to bitcoin mining said a group wants to buy a controlling stake from Cango's co-founders
Cango Inc.&nbsp;(CANG.US)&nbsp;<a href="https://www.prnewswire.com/news-releases/cango-inc-announces-receipt-of-a-preliminary-non-binding-letter-of-intent-and-formation-of-special-committee-302401855.html#:~:text=(NYSE%3A%20CANG)%20(%22,its%20non%2Dbinding%20intent%20to">said on Friday</a>&nbsp;it has been approached by an investor interested in taking control of the company, representing the first such bid since its pivot late last year from car trading services to bitcoin mining. Such offers typically carry big premiums to a company's current value, which for Cango currently stands at about $400 million.
Cango said it received the non-binding letter of intent to obtain control of the company from Enduring Wealth Capital Ltd., which wants to acquire 10 million Class-B shares held by Cango co-founders Zhang Xiaojun and Lin Jiayuan. Zhang is currently Cango's chairman, while Lin is its CEO. Zhang held 22.8% of Cango's ordinary shares with 48.4% of its voting power at the end of 2023, while Lin held 22.4% with 44.1% of the voting power, according to the company's latest annual report filed last April.
Enduring Wealth said it would like to purchase the 10 million shares from the co-founders "at a purchase price in cash to be agreed among the parties," according to Cango. As part of any agreement, Cango's management would be "restructured in such manner as requested by Enduring Wealth Capital," the statement added.
Furthermore, any deal would likely require Cango to dispose of its existing car-trading business in China, with Enduring Wealth offering to "introduce a potential buyer." Such moves would allow Cango, which is based in China but operates its bitcoin mining business outside the country, to terminate its status as a "China concept stock" with the U.S. securities regulator.
Enduring Capital's key decision makers are Andrea Dal Mas and Yu Peng, who are both directors of the company. Dal Mas' LinkedIn profile describes him as a managing partner at Singapore-based Antalpha Ventures, "where he focuses on strategic investments in blockchain technology and artificial intelligence companies." Cango described Yu as "a seasoned and accomplished finance professional with extensive experience in investment management and asset management." Yu was described as Antalpha's chief strategy officer in an August 2024 announcement from virtual asset manager Pando.
Cango said its board resolved to form a committee consisting of its three independent directors to consider the proposal.
Cango's shares rose 14.6% in Friday trading after the announcement. The company's stock is up nearly 150% over the last six months, most of that coming after Cango announced its entry into the bitcoin mining business last November. Before that, the company was mostly focused on the car business in China, starting as an auto financer before more recently shifting its business to auto trading services.
Cango used its large cash reserves to enter the bitcoin mining business, purchasing $250 million worth of mining machines with plans to acquire another $150 million worth. The company began mining bitcoins in November and had mined 1,944.2 bitcoins through the end of February.
Following its entry to the bitcoin mining business, the company's revenue jumped by more than a factor of five to 668 million yuan ($92 million) in last year's fourth quarter from 130.2 million a year earlier. Most of that came from the new bitcoin mining business, though the company continues to operate its car-trading business that offers both domestic and transborder trading services.

Equities

Signals

CANG

Cango Stock Rises ~15% On Buyout Interest

Truist Securities analyst Neal Dingmann maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and lowers the price target from $133 to $131.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Expand Energy, Lowers Price Target to $131

UBS analyst Manav Gupta upgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Sell to Neutral and lowers the price target from $15 to $12.

Upgrades

CLMT

UBS Upgrades Calumet to Neutral, Lowers Price Target to $12

Truist Securities analyst Bertrand Hodee maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Hold and raises the price target from $35 to $37.

Truist Securities Maintains Hold on Range Resources, Raises Price Target to $37

Citigroup analyst Andrew Kaplowitz reinstates Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and announces $132 price target.

Initiation

Citigroup Reinstates Buy on Emerson Electric, Announces $132 Price Target

Science Applications International Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday after the fourth-quarter FY25 earnings.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44352871/saic-announces-fourth-quarter-and-full-fiscal-year-2025-results" rel="noreferrer noopener">fourth-quarter sales growth </a>of 6% year-on-year to $1.84 billion, beating the analyst consensus estimate of $1.81 billion.
Adjusted EPS of $2.57 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus </a>estimate of $2.08.
The operating income for the quarter jumped 75% to $138 million and the operating margin expanded by 300 basis points to 7.5%.
Adjusted EBITDA increased 39% to $177 million with an adjusted EBITDA margin of 9.6%, a 230 basis points expansion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details" rel="noreferrer noopener">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a>
Net bookings for the quarter were approximately $1.3 billion, which reflects a book-to-bill ratio of approximately 0.7.  The operating cash flow for the quarter totaled $115 million, with transaction-adjusted free cash flow of $236 million.
SAIC&#8217;s estimated backlog at the end of fiscal year 2025 was approximately $21.9 billion of which $3.4 billion was funded. The company held $64 million in cash and equivalents as of January 31, 2025.
&#8220;Subsequent to quarter close, we received a $1.8 billion award for our largest recompete win in recent years, the System Software Lifecycle Engineering program. This important win along with&nbsp;a backlog of submitted bids valued at approximately $20 billion reflect the momentum we are building inside the company,&#8221; said CEO Toni Townes-Whitley.
Outlook: Science Applications revised the FY26 revenue outlook from $7.55 billion &#8211; $7.75 billion to $7.60 billion &#8211; $7.75 billion versus an estimate of $7.644 billion.
The company also raised the FY26 adjusted EPS outlook from $8.90 &#8211; $9.10 to $9.10 &#8211; $9.30 against an estimate of $9.07.
Price Action: SAIC shares traded higher by 9.16% at $114.00 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44327146/whats-going-on-with-palantir-technologies-stock-today" target="_blank" rel="noreferrer noopener">Palantir Technologies Partners With RCM Company R1For AI Lab</a></li>
</ul>

Earnings

Guidance

Movers

General

SAIC

Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains

Citigroup analyst Lydia Ling downgrades RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) from Buy to Neutral and lowers the price target from $2.8 to $2.5.

Downgrades

Citigroup Downgrades RLX Technology to Neutral, Lowers Price Target to $2.5

Earnings Beats

SBET

SharpLink Gaming FY24 EPS $2.29 Up From $(5.19) YoY; Revenue $3.662M Down From $4.952M YoY

Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) ("Guess?" or the "Company") today announced that its Board of Directors (the "Board") has received a non-binding proposal from WHP Global through its affiliate WHP Investments, LLC, to acquire for $13.00 per share in cash the outstanding shares of Guess?, Inc., other than shares held by certain existing shareholders, including Paul Marciano, Maurice Marciano and Carlos Alberini (collectively, the "Proposed Rollover Shareholders"). The proposal contemplates that the proposed transaction would be financed through a combination of equity and third-party debt financing, as well as rollover or reinvestment by each of the Proposed Rollover Shareholders, and assumes that the Company will operate in the ordinary course of business and that there will be no material change to the strategic and operational position of the Company.
Guess? has formed a Special Committee of independent and disinterested directors of the Board (the "Special Committee") to evaluate the proposal, with the assistance of outside financial and legal advisors, to determine the course of action that is in the best interest of Guess? and its shareholders.
There is no guarantee that any definitive offer will be made, that any agreement will be executed or that the proposed transaction in the proposal or any other transaction will be approved or completed. Guess? does not intend to comment further on this matter until the Special Committee has completed its evaluation of the proposal or until further disclosure is deemed appropriate. Guess? shareholders do not need to take any action at this time.
In April 2024, the Company partnered with WHP Global to acquire the intellectual property and operating assets of New York-based fashion brand rag &amp; bone, a leader in the American fashion scene, with the Company directly operating rag &amp; bone stores in the U.S. and in the U.K., and also having rag &amp; bone available in high-end boutiques, department stores and through e-commerce globally.

Guess? Receives Non-Binding Going-Private Proposal From WHP Global; To Acquire The Company For  $13.00 Per Share In Cash

SIDU

Sidus Space Announces Launch, Deployment And Operation Of LizzieSat-3

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining stocks just hit a rough patch. According to JPMorgan analyst Reginald L. Smith, <a href="https://www.benzinga.com/topic/bitcoin-miners">U.S.-listed miners</a> are now trading at just 1.35x their proportional share of the four-year block reward opportunity &#8211; marking the first time in nearly a year that valuations have fallen below the 1.7x historical average since January 2022.
<h2 class="wp-block-heading">Bitcoin Price Drops, Mining Competition Rises</h2>
The culprit? A combination of Bitcoin's price decline and rising mining competition. March saw Bitcoin&#8217;s average price drop 10% to $85,600, briefly dipping as low as $79,000.
Related: <a href="http://Bitcoin Drop Shakes Crypto Stocks As Coinbase, Robinhood, MARA, Riot Dip: Do Traders See A Bargain?">Bitcoin Drop Shakes Crypto Stocks As Coinbase, Robinhood, MARA, Riot Dip: Do Traders See A Bargain?</a>
Meanwhile, network hashrate, a key measure of mining difficulty, climbed to an average of 811 EH/s, up 35% year-over-year. With more miners vying for a slice of the pie, daily mining profitability continues to erode.
<h2 class="wp-block-heading">Mining Stocks Struggle, Market Cap Takes A Hit</h2>
Mining stocks have taken it on the chin. From Feb. 28 to March 15, the combined market cap of the 14 U.S.-listed miners JPMorgan tracks fell 13% &#8211; recording a $3 billion hit. 
Just one miner outperformed Bitcoin's price movement in that span. Cipher Mining Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) led the losers, dropping 25%, while Argo Blockchain PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) was the lone bright spot, eking out a 1% gain.
<h2 class="wp-block-heading">US-Listed Miners Hold Market Share</h2>
Despite the challenges, U.S.-listed miners have held their ground in terms of market share. They added roughly 1 EH/s since late January, keeping their slice of the global hashrate steady at around 30%. 
Bitfarms Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) and CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) led the charge, while Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) and Hut 8 Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) saw slight declines in self-mining capacity.
For now, the sector is caught in a squeeze—declining Bitcoin prices and increased competition are making mining a tougher business. With valuations slipping below long-term averages, the question remains: Are investors overreacting or is this a sign of tougher days ahead?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44353212/can-bitcoins-ibit-surpass-spy-to-become-the-largest-etf-we-asked-ai-bots-perplexity-and-grok-this-question-and-heres-how-they-responded">Can Bitcoin&#8217;s IBIT Surpass SPY To Become The Largest ETF? We Asked AI Bots Perplexity And Grok This Question, And Here&#8217;s What They Said</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

Tech

Trading Ideas

$BTC

ARBK

BITF

CIFR

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

Bitcoin Miners Hit Rock Bottom? Valuations Slip Below Key Average For First Time In A Year

PepsiCo To Acquire poppi For $1.95B, Net Purchase Price $1.65B

Macquarie analyst Eugene Hsiao downgrades Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) from Outperform to Neutral and announces $27 price target.

Macquarie Downgrades Li Auto to Neutral, Announces $27 Price Target

<ul>
<li>Data Reinforce the Clinically Meaningful Impact of&nbsp;INGREZZA in Adults with Huntington's Disease Chorea
<ul>
<li>Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium</li>
</ul>
</li>
</ul>

Biotech

Events

NBIX

Neurocrine Biosciences Presents Data From KINECT-HD Study

Management

Aon Announces Eric Andersen Has Transitioned From His Role As President To Serve As A Senior Advisor To Greg Case, CEO Of Aon, Through June 2026; The Role Of President Has Been Assumed By Greg Case

ICCM

IceCure Receives Notice Of Allowance In China Titled 'Cryogenic System Connector'

WIIM

American Eagle Outfitters shares are trading higher after the company announced a $200 million accelerated share repurchase program with Bank of America, N.A.

PLCE

The Children's Place Appoints John Szczepanski As CFO

Buybacks

LMNR

Limoneira Board Approves $30M Buyback

American Eagle Outfitters Announces $200M Accelerated Share Repurchase Program With Bank Of America

Press Releases

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Health Care

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Comments

BioCardia

BioCardia (BCDA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL